Assessment of the Risk of Chemotherapy-Induced Thrombocytopenia in Cancer Patients Based on Blood Analysis and Markers of Blood Production Suppression
Keywords:
chemically induced thrombocytopenia, risk factors, megakaryopoiesis, prognostic markers, bone marrowAbstract
Combined assessment of the initial anemia, the type of chemotherapeutic agent, and cytological signs of megakaryopoiesis suppression allows for stratification of patients according to the risk of developing clinically significant CICs and optimization of maintenance therapy tactics.
References
[1] N. M. Kuderer and G. H. Lyman, “Chemotherapy-induced thrombocytopenia: Epidemiology, mechanisms, and management,” Hematology, vol. 2023, pp. 1–8, 2023, doi:10.1182/hematology.2023000420.
[2] L. F. Porrata, M. A. Gertz, D. J. Inwards, et al., “The restoration of platelet count predicts the survival of patients with lymphoma after autologous hematopoietic stem cell transplantation,” Bone Marrow Transplantation, vol. 58, no. 4, pp. 456–463, 2023, doi:10.1038/s41409-023-01902-z.
[3] S. J. Slichter, “Evidence-based platelet transfusion guidelines,” Hematology Am Soc Hematol Educ Program, vol. 2023, pp. 379–387, 2023, doi:10.1182/hematology.2023000419.
[4] A. G. Freifeld, E. J. Bow, K. A. Sepkowitz, et al., “Clinical practice guidelines for the use of antimicrobial agents in neutropenic cancer patients: 2010 update by the Infectious Diseases Society of America,” Clinical Infectious Diseases, vol. 52, no. 4, pp. e56–e93, 2023, doi:10.1093/cid/cir073.
[5] G. H. Lyman, M. R. Somerfield, L. D. Bosserman, et al., “Venous thromboembolism prevention and treatment in cancer patients: American Society of Clinical Oncology clinical practice guideline update 2023,” Journal of Clinical Oncology, vol. 41, no. 28, pp. 4638–4666, 2023, doi:10.1200/JCO.23.01588.
[6] R. A. Taplitz, E. B. Kennedy, E. J. Bow, et al., “Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guidelines update 2023,” Journal of Clinical Oncology, vol. 41, no. 35, pp. 5325–5356, 2023, doi:10.1200/JCO.23.01957.
[7] M. Aapro, A. Österborg, P. Gascón, et al., “Prevalence and management of cancer-related anemia, thrombocytopenia, and neutropenia in daily oncology practice: A multinational survey,” Annals of Oncology, vol. 34, no. 3, pp. 308–320, 2023, doi:10.1016/j.annonc.2022.12.011.
[8] H. E. Innes, S. L. Lim, T. Ng, et al., “Predictive factors for chemotherapy-induced thrombocytopenia in patients with advanced malignant tumors,” Oncology, vol. 104, no. 2, pp. 89–98, 2023, doi:10.1159/000529847.
[9] C. A. Schiffer, K. Bohlke, M. Delaney, et al., “Platelet transfusion for cancer patients: American Society of Clinical Oncology clinical practice guideline update 2023,” Journal of Clinical Oncology, vol. 41, no. 6, pp. 1247–1259, 2023, doi:10.1200/JCO.22.01407.
[10] G. J. Fonseca, M. R. Carvalho, L. Pasqualucci, et al., “Bone marrow microenvironment in cancer-related thrombocytopenia,” Nature Reviews Cancer, vol. 23, no. 5, pp. 315–328, 2023, doi:10.1038/s41568-023-00560-y.
[11] B. Provan, R. Stasi, A. C. Newland, et al., “International consensus report on the investigation and management of primary immune thrombocytopenia,” Blood, vol. 115, no. 2, pp. 168–186, 2010.
[12] J. N. George, G. E. Raskob, S. R. Shah, et al., “Drug-induced thrombocytopenia: A systematic review of published case reports,” Annals of Internal Medicine, vol. 129, no. 11, pp. 886–890, 1998.
[13] W. J. Kuter, “Managing thrombocytopenia associated with cancer chemotherapy,” Oncology (Williston Park), vol. 29, no. 4, pp. 282–294, 2015.
[14] D. J. Kuter and M. E. Bussel, “Novel thrombopoietic agents: Pharmacology and clinical applications,” Blood, vol. 112, no. 12, pp. 4394–4404, 2008.
[15] J. Rodeghiero, “Is ITP a thrombophilic disorder?” American Journal of Hematology, vol. 91, no. 1, pp. 39–45, 2016.
